Feasibility Phase Underway: Apifa Biotech, Konza Technopolis, and Swedfund Sign Study Agreements

Kenya’s planned Biopharma Life Sciences Park at Konza Technopolis has the potential to gradually ease medicine costs over the long term, though whether patients experience lower prices at the pharmacy counter will depend on supply chain efficiency, production scale, and distribution markups rather than factory output alone.

On Thursday, November 12, 2026, project proponent Apifa Biotech, the Technopolis Development Authority, and Swedfund International signed agreements in Nairobi to finance and launch a technical and commercial feasibility study—to be conducted by a consortium of Jones Lang LaSalle (JLL) and IQVIA—marking a key preparatory milestone for the proposed 200-acre, US$217 million (approximately KSh 28.2 billion) facility.

Currently, Kenya imports roughly 70 per cent of its pharmaceutical products, leaving retail drug prices vulnerable to global supply chain shocks, freight charges, and foreign exchange fluctuations.

Structured in two phases—beginning with shared laboratories, testing centers, and logistics infrastructure before onboarding seven to ten major pharmaceutical manufacturers—the Konza hub aims to localize the production of finished medicines, vaccines, diagnostics, and Active Pharmaceutical Ingredients (APIs).

Coupled with Special Economic Zone (SEZ) tax incentives such as customs duty exemptions on raw materials and capital machinery, localizing API and bulk drug manufacturing could significantly lower baseline production costs.

However, analysts note that establishing a manufacturing park does not automatically guarantee cheaper retail medicines.

Final prices paid by Kenyans at chemists are heavily shaped by downstream expenses, including wholesale margins, storage, transport, and multiple intermediaries between the factory gate and the consumer.

With the project still at the feasibility stage ahead of financing and construction, meaningful relief for patients will ultimately hinge on high-volume generic competition, streamlined procurement by public agencies and private pharmacies, and passing factory-level savings directly to households.

What are your thoughts about this article? Share your reactions in the comment section and don’t forget to share and follow for more updates.

https://peopledaily.digital/insights/how-konzas-planned-biopharma-park-could-affect-medicine-prices-in-kenya

BigdNews feedback-opera-news-app@opera.com